Logo

American Heart Association

  14
  0


Final ID: MDP1502

The Use of Angiotensin Receptor Blockers Decreased Three-Year and Five-Year Mortality in a VA Population with Ascending Thoracic Aortic Aneurysms

Abstract Body (Do not enter title and authors here): Background:
The incidence of ascending thoracic aortic aneurysms (aTAA) is approximately 5-10/100000 individuals/year. Estimates of acute rupture or dissection range from 1.6-4/100000 individuals/year with a mortality rate for untreated dissection up to 50% within 48 hours. Current guidelines recommend surgical intervention for aTAAs ≥ 55mm in diameter. Risk factors that contribute to aTAA growth and mortality include diabetes, age, and smoking history however, not much investigation has been done to evaluate protective factors.

Objective:
To evaluate clinical factors that reduce three-year and five-year all-cause mortality in a veteran population who have dilated ascending aortas or ascending thoracic aortic aneurysms (aTAA) and who did not undergo repair within three or five years.

Methods:
We conducted a cohort study of 887 patients followed for aTAA (diameter ≥ 4.0cm) at a Veterans Affairs hospital. Patients who died of any cause before repair within 3 or 5 years of aTAA identification or had 3 or 5 years of follow-up without repair were further analyzed. 57 pertinent factors (including social, genetic, cardiac risk factors, aneurysm size, medications, etc.) were evaluated in univariate logistic regression models of three and five-year all-cause mortality. Variables with univariate p<0.2 were combined in a multivariate logistic regression model. P<0.05 was considered statistically significant.

Results:
In the 3-year model, 392 had ≥3 years follow-up without aTAA surgical repair. 35 out of 392 patients (8.9%) died within 3 years. The only statistically significant variable that reduced mortality was history of angiotensin receptor blocker (ARB) use (OR 0.24, p=0.042). In the 5-year model, 274 had ≥5 years follow-up without aTAA surgical repair. 68 out of 274 patients (24.8%) died within 5 years. Similarly, history of ARB use (OR 0.22, p=0.003) was the only pertinent variable. For both models, the results were independent of age, history of diabetes, valve disease, CHF, and stroke.

Conclusion:
Among modifiable risk factors, at both 3 and 5 years, history of ARB was associated with reduced mortality (13% mortality compared to 27% at 5 years) and should be further investigated.
  • Kailash, Vidur  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Tu, Sally  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Zamirpour, Siavash  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Pace, William  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Boskovski, Marko  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Ge, Liang  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Tseng, Elaine  ( UCSF AND SFVAMC , San Francisco , California , United States )
  • Author Disclosures:
    Vidur Kailash: DO NOT have relevant financial relationships | Sally Tu: DO NOT have relevant financial relationships | Siavash Zamirpour: DO NOT have relevant financial relationships | William Pace: DO NOT have relevant financial relationships | Marko Boskovski: DO have relevant financial relationships ; Consultant:Edwards Lifesciences:Active (exists now) | Liang Ge: DO have relevant financial relationships ; Ownership Interest:ReValve Med Inc.:Active (exists now) | Elaine Tseng: DO have relevant financial relationships ; Research Funding (PI or named investigator):Artivion Inc:Past (completed) ; Research Funding (PI or named investigator):Ottawa Heart Institute:Active (exists now) ; Research Funding (PI or named investigator):Potrero:Past (completed) ; Research Funding (PI or named investigator):Cellphire:Past (completed) ; Research Funding (PI or named investigator):Amgen Inc:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Advances in Aortic Health Research: Insights from Recent Studies

Monday, 11/18/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
A Hard Start: Early, Intensive Healthcare Utilization for Children with Critical Congenital Heart Disease

Ellis Danielle, Hall Matthew, Blume Elizabeth, Wolfe Joanne, Snaman Jennifer, Berry Jay

Cross-talk between oxidized LDL, oxidative stress and renin-angiotensin-aldosterone system: Impact on endothelial function and atherosclerosis

Catar Rusan, Cybularz Maria, Hengst Clara, Villar Ballesteros Maria De Leyre, Lehmann Susann, Schubert Undine, Ludwig Barbara, Ziegler Christian, Bornstein Stefan, Krug Alexander, Walther Thomas, Kamhieh-milz Julian, Moll Guido, Morawietz Henning, Goettsch Claudia, Chen Lei, Zickler Daniel, Taye Ashraf, Hofmann Anja, Brunssen Coy, Muller Gregor

You have to be authorized to contact abstract author. Please, Login
Not Available